Reassuring Data on Durability of Long-Acting ART Every 8 Weeks

After 3 years, high rates of viral suppression were observed with long-acting cabotegravir plus rilpirivine every 4 or 8 weeks.

Long-acting cabotegravir plus rilpivirine (LA CAB+RPV) was FDA approved based on 48- or 96-week results of the FLAIR, ATLAS, and ATLAS-2M studies. Despite high interest among patients, logistic issues have hampered this regimen's use. Now, ATLAS-2M investigators report 152-week outcomes in 1045 persons suppressed on oral antiretroviral therapy (ART) who were randomly assigned 1:1 to dosing every 8 weeks (Q8W) or 4 weeks (Q4W).

At week 152, efficacy of Q8W LA CAB+RPV was noninferior to Q4W (87% and 86% with HIV RNA <50 copies/mL, respectively). Rates of confirmed virologic failure (CVF) were 2.3% (Q8W) versus 0.4% (Q4W). Two cases of CVF occurred in the Q8W arm after week 96 whereas no cases occurred in the Q4W arm after week 48. Throughout 1…

Reviewing Author

Keith Henry, MD

Disclosures

Consultant/Advisory BoardViiV Advisory Board

Editorial BoardsJAIDS: Journal of Acquired Immune Deficiency Syndromes

Keith Henry, MD

Disclosures

Consultant/Advisory BoardViiV Advisory Board

Editorial BoardsJAIDS: Journal of Acquired Immune Deficiency Syndromes

Reassuring Data on Durability of Long-Acting ART Every 8 Weeks

Topics

Reviewing Author